Form 4 for TVGN Tevogen Inc.
Accepted 2024-06-07 00:00:00 ET · period of report 2024-06-05 · accession 0001062993-24-012192 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-07 | 2024-06-05 | TVGN | Saadi Ryan H. | CEO, Dir, 10% | P - Purchase | $0.77 | +2,607 | 118.25M | +0.0% | +$2,008 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-05 | P | A | 2,607.32 | $0.77 | 118,252,659.32 | D | — | — | (F1) The price reported in Column 4 represents a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7635 to $0.7671, inclusive. The reporting person undertakes to provide to Tevogen Bio Holdings Inc., any security holder of Tevogen Bio Holdings Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |